The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury - Authors' reply

Jing Ye; Zhen Wang; Ying Huang; Menglong Wang; Bin Que; Di Ye; Yao Xu; Yuan Wang; Tao Zeng; Yingzhong Lin; Jun Wan; Qingwei Ji

doi:10.1016/j.ebiom.2018.08.049

The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury - Authors' reply

EBioMedicine. 2018 Sep:35:4-5. doi: 10.1016/j.ebiom.2018.08.049. Epub 2018 Aug 30.

Authors

Jing Ye¹, Zhen Wang², Ying Huang³, Menglong Wang⁴, Bin Que⁵, Di Ye⁴, Yao Xu⁴, Yuan Wang⁴, Tao Zeng⁶, Yingzhong Lin⁷, Jun Wan⁸, Qingwei Ji⁹

Affiliations

¹ Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China; Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Department of Cardiology, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
² Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China; Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan 430060, China.
³ Department of Ultrasound, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
⁴ Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan 430060, China.
⁵ Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China.
⁶ Department of Cardiology, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
⁷ Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Department of Cardiology, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. Electronic address: yingzhonglin@126.com.
⁸ Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan 430060, China. Electronic address: wanjun@whu.edu.cn.
⁹ Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China. Electronic address: jqw124@163.com.

No abstract available

MeSH terms

Animals
Antineoplastic Agents / adverse effects*
Doxorubicin / adverse effects
Heart Injuries / chemically induced*
Humans
Interleukin-12 / therapeutic use*
Interleukins / therapeutic use*
Mice

Substances

Antineoplastic Agents
Interleukins
Interleukin-12
Doxorubicin